Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

GRF312

Plasma-derived product · developed by Instituto Grifols

Phase 2 Most advanced trial (none active)

GRFS Developer

1 Registered trials

What is GRF312?

GRF312 is a 5% ophthalmic solution of human immune globulin. It is being studied in dry eye disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Plasma-derived product
Therapy area: Ophthalmology
Developer: Instituto Grifols, S.A. (GRFS)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07264517	Phase 2	Dry Eye Disease	Completed	GRFS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Dry Eye Disease

More from Instituto Grifols

albumin human, USP FDA approved Antithrombin III FDA approved factor VIII / von Willebrand factor FDA approved Alpha-1 Phase 3 C19-IG Phase 3 Fibrin Sealant Grifols Phase 3 Human Plasma-Derived Fibrinogen Concentrate Phase 1/2 IVIG-PEG Phase 3 plasma-derived FVIII/VWF concentrate Phase 4

Sources

ClinicalTrials.gov NCT07264517

Updated Oct 11, 2026. Something wrong or missing? Report it on the GRFS page.

Follow GRFS, the company behind GRF312

See GRFS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GRFS catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z